Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of CM336 Injection for Active Sjogren's Syndrome: an Open-Label Phase Ib Study

NCT07642843 is registered in ClinicalTrials.gov with Keymed Biosciences Co.Ltd as lead sponsor.

NCT NCT07642843
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07642843 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of CM336 Injection for Active Sjogren's Syndrome: an Open-Label Phase Ib Study
Lead sponsor
Keymed Biosciences Co.Ltd
Phase
Phase 1
Overall status
Not yet recruiting
Start date
June 30, 2026
Completion date
February 28, 2029
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary sjögren's syndrome (pss)